QR Code

Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV

Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles. The LS mutation delays antibody clearance by enhancing binding affinity to the neonatal fragment crystal...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Bryan T. Mayer, Lily Zhang, Allan C. deCamp, Chenchen Yu, Alicia Sato, Heather Angier, Kelly E. Seaton, Nicole Yates, Julie E. Ledgerwood, Kenneth Mayer, Marina Caskey, Michel Nussenzweig, Kathryn Stephenson, Boris Julg, Dan H. Barouch, Magdalena E. Sobieszczyk, Srilatha Edupuganti, Colleen F. Kelley, M. Juliana McElrath, Huub C. Gelderblom, Michael Pensiero, Adrian McDermott, Lucio Gama, Richard A. Koup, Peter B. Gilbert, Myron S. Cohen, Lawrence Corey, Ollivier Hyrien, Georgia D. Tomaras, Yunda Huang
Hōputu: Artigo
Reo:Inglês
I whakaputaina: MDPI AG 2024-04-01
Rangatū:Pharmaceutics
Ngā marau:
monoclonal antibodies
LS mutation
two-compartment model
population pharmacokinetics modeling
HIV prevention
targeted maximum likelihood estimation (TMLE)
Urunga tuihono:https://www.mdpi.com/1999-4923/16/5/594
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite